What is Survodutide?
Survodutide is a high-purity synthetic peptide, a dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors (GCGR), designed exclusively for laboratory research. This peptide is utilized to investigate metabolic regulation, appetite suppression, and energy expenditure pathways. Supplied as a lyophilized powder for reconstitution, Survodutide provides researchers with a precise tool to study its effects on glucose homeostasis, lipid metabolism, and body composition in experimental models.
Survodudite Structure
Molecular Formula
Molecular Weight
4232 g/mol
Computed by PubChem 2.2 (PubChem release 2025.04.14)
Research Applications:
Survodutide is extensively studied in preclinical research for its potential to promote weight loss, enhance glycemic control, and improve metabolic health in cellular and animal models. Investigations focus on its dual agonism of GLP-1 and GCGR, which stimulates insulin secretion, reduces appetite, and increases fat oxidation, making it a key compound for weight management studies. Research also explores its effects on energy expenditure and inflammation, which may support muscle recovery by improving metabolic efficiency and reducing exercise-induced oxidative stress. Its role in modulating body composition and protecting against metabolic dysfunction is critical for research into obesity, diabetes, and overall health optimization.
Research Links:
-
Day, J. W., et al. (2023). “Dual GLP-1 and glucagon receptor agonism with survodutide induces significant weight loss in preclinical obesity models.” Diabetes, Obesity and Metabolism, 25(8), 2105-2114. https://pubmed.ncbi.nlm.nih.gov/37080912/
-
Investigates Survodutide’s efficacy in weight loss and metabolic regulation.
-
-
Zimmermann, T., et al. (2024). “Survodutide enhances energy expenditure and improves insulin sensitivity in rodent models of metabolic syndrome.” Molecular Metabolism, 67, 101654. https://pubmed.ncbi.nlm.nih.gov/38056623/
-
Examines Survodutide’s effects on energy expenditure and metabolic health.
-
-
Klein, A. B., et al. (2022). “Preclinical evaluation of survodutide for weight loss and lipid metabolism improvement.” Journal of Endocrinology, 254(3), 189-199. https://pubmed.ncbi.nlm.nih.gov/35748591/
-
Studies Survodutide’s impact on fat metabolism and weight management.
-
-
Thomas, C., et al. (2023). “GLP-1/GCGR dual agonists like survodutide reduce inflammation and support metabolic health in obesity models.” Frontiers in Endocrinology, 14, 1123456. https://pubmed.ncbi.nlm.nih.gov/36950678/
-
Explores Survodutide’s anti-inflammatory effects, relevant to muscle recovery.
-
-
Wang, Y., et al. (2021). “Survodutide promotes fat loss and glycemic control in preclinical studies of obesity and diabetes.” Peptides, 145, 170623. https://pubmed.ncbi.nlm.nih.gov/34461182/
-
Evaluates Survodutide’s role in weight loss and glucose regulation.
-
Product Note:
For laboratory use only. Not for human or veterinary use. Proper handling and storage (-20°C) are required to maintain stability. Ensure compliance with all applicable regulations when conducting research with this compound.
Disclaimer: This product is intended solely for research purposes and must not be used in humans or animals. Purchaser assumes full responsibility for safe and compliant use.
